icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022
Back grey_arrow_rt.gif
 
 
 
A 52-Week Phase 3 Clinical Trial of Resmetirom
in 180 Patients With Well-Compensated NASH Cirrhosis

 
 
  AASLD 2022 Nov 4-8
 
Stephen A. Harrison,1 Naim Alkhouri,2 Rebecca A. Taub,3 Guy W. Neff,4 Kris V. Kowdley,5 Mazen Noureddin6 1University of Oxford, United Kingdom & Pinnacle Clinical Research, San Antonio, TX; 2Arizona Liver Health, Tucson, AZ; 3Madrigal Pharmaceuticals, Conshohocken, PA; 4Covenant Metabolic Specialists, Sarasota, FL;
5Liver Institute Northwest, Seattle, WA; 6Houston Research Institute, Houston, TX

1108221

1108222

1108223

1108224

1108225

1108226